top of page

N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works

Sep 2, 2025

1 min read

He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run faster and more efficient trials, and offer more participants a chance to be in experimental arms.

https://vimeo.com/1115355222?share=copy

Recent Posts

HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator

HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab

HCW 2026: Trevi Therapeutics was founded under the premise that cough is a brain problem, not a lung problem - it seems to be playing out in the clinic

HCW 2026: Trevi Therapeutics was founded under the premise that cough is a brain problem, not a lung problem - it seems to be playing out in the clinic

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page